Takahashi Saeko, Kaneda Hideaki, Tanaka Shinji, Miyashita Yusuke, Shiono Takaaki, Taketani Yoshio, Domae Hiroshi, Matsumi Junya, Mizuno Shingo, Minami Yoshiyasu, Sugitatsu Kazuya, Saito Shigeru
Division of Cardiology & Catheterization Laboratories, Heart Center of Shonan Kamakura General Hospital, Japan.
Circ J. 2007 Feb;71(2):226-8. doi: 10.1253/circj.71.226.
Although drug-eluting stents dramatically reduce revascularization after percutaneous coronary intervention (PCI), it is still unclear whether they increase the risk of stent thrombosis. Late stent thrombosis (>30 days) was a very rare complication after bare metal stent implantation. Four cases of confirmed late angiographic stent thrombosis (LAST) after sirolimus-eluting stent (SES) implantation are presented and the incidence, promoting factors and outcomes of such cases in Japan, where clopidogrel has not been approved, are described.
Between September 2004 and March 2006, 725 patients underwent PCI with SES implantation and 679 patients (94%) were clinically followed up (median 271 days). There were 4 cases (0.6%) of LAST (at 60, 180, 215, and 508 days, respectively) after elective SES implantation resulting in myocardial infarction. Three cases occurred soon after antiplatelet therapy discontinuation 3 patients died after LAST events. The incidence of LAST was 0.6%.
LAST is a rare complication, even after SES implantation, at least in patients with appropriate antiplatelet therapy. However, as it can lead to fatal complications, it must be taken into account, especially when antiplatelet therapy is discontinued.
尽管药物洗脱支架显著降低了经皮冠状动脉介入治疗(PCI)后的血管再通率,但它们是否会增加支架血栓形成的风险仍不清楚。晚期支架血栓形成(>30天)在裸金属支架植入后是一种非常罕见的并发症。本文报告了4例西罗莫司洗脱支架(SES)植入后经血管造影确诊的晚期支架血栓形成(LAST)病例,并描述了在氯吡格雷未获批准的日本此类病例的发生率、促发因素及结果。
2004年9月至2006年3月期间,725例患者接受了SES植入的PCI治疗,679例患者(94%)接受了临床随访(中位随访时间271天)。择期SES植入后有4例(0.6%)发生LAST(分别在60、180、215和508天),导致心肌梗死。3例在停用抗血小板治疗后不久发生,3例患者在LAST事件后死亡。LAST的发生率为0.6%。
LAST是一种罕见的并发症,即使在SES植入后也是如此,至少在接受适当抗血小板治疗的患者中是这样。然而,由于它可导致致命并发症,必须予以考虑,尤其是在停用抗血小板治疗时。